News coverage about Sarepta Therapeutics (NASDAQ:SRPT) has trended somewhat positive recently, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sarepta Therapeutics earned a daily sentiment score of 0.23 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 46.1421636644897 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news articles that may have effected Accern Sentiment’s scoring:
Shares of Sarepta Therapeutics (SRPT) opened at $64.00 on Friday. Sarepta Therapeutics has a 52 week low of $26.96 and a 52 week high of $68.90. The company has a debt-to-equity ratio of 0.04, a quick ratio of 9.52 and a current ratio of 10.44. The firm has a market cap of $4,190.00, a price-to-earnings ratio of -31.37 and a beta of 1.49.
A number of equities analysts have recently commented on the stock. BidaskClub lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 10th. HC Wainwright set a $75.00 price target on shares of Sarepta Therapeutics and gave the company a “buy” rating in a research report on Monday, February 12th. William Blair reissued an “outperform” rating on shares of Sarepta Therapeutics in a research report on Monday, February 5th. Zacks Investment Research upgraded shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, February 7th. Finally, Barclays restated a “hold” rating and issued a $55.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, January 23rd. One research analyst has rated the stock with a sell rating, six have given a hold rating and seventeen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $64.65.
In other news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the business’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $55.89, for a total value of $372,618.63. Following the sale, the director now owns 13,333 shares in the company, valued at approximately $745,181.37. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 9.60% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: This report was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/18/sarepta-therapeutics-srpt-receiving-somewhat-positive-news-coverage-study-shows.html.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.